www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 65), pp: 108316-108332 Priority Research Paper The PAX8 cistrome in epithelial ovarian cancer Emily K. Adler1,*, Rosario I. Corona2,3,*, Janet M. Lee2, Norma Rodriguez-Malave2, Paulette Mhawech-Fauceglia4, Heidi Sowter5, Dennis J. Hazelett2,**, Kate Lawrenson2,3,** and Simon A. Gayther2,3,** 1 Department of Preventive Medicine, University of Southern California/Keck School of Medicine, Los Angeles, California, USA 2 Center for Bioinformatics and Functional Genomics, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA 3 Women’s Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA 4 Departments of Medicine and Pathology, University of Southern California/Keck School of Medicine, Los Angeles, California, USA 5 Department of Biomedical Science and Public Health, University of Derby, Derby, UK * These authors have contributed equally to this study ** Jointly lead the study Correspondence to: Kate Lawrenson, email:
[email protected] Correspondence to: Simon A. Gayther, email:
[email protected] Keywords: PAX8, transcription factor, ovarian cancer, chromatin immunoprecipitation, ChIP-seq Received: August 24, 2017 Accepted: September 30, 2017 Published: November 27, 2017 Copyright: Adler et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT PAX8 is a lineage-restricted transcription factor that is expressed in epithelial ovarian cancer (EOC) precursor tissues, and in the major EOC histotypes.